New chairman at Chiroscience
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.CHIROSCIENCE, the UK's second-biggest biotechnology company, has named SmithKline Beecham executive Hugh Collum (left) as its next chairman, a move that analysts say could raise the company's profile.
Mr Collum, 58, who is currently SmithKline's finance director, will replace Lord Henry Chilver, who said earlier this year he would leave his post. His appointment takes effect from the 1 October.
Before joining SmithKline Beecham in 1987, Mr Collum was finance director of Cadbury Schweppes, the maker of Dr Pepper and Seven Up and now the world's third-largest soft-drinks maker.
Like most biotechnology companies, Chiroscience is still reporting losses while it develops what it hopes will be profitable drugs, and analysts said Mr Collum's nomination could help raise the company's profile.
It expects this year to start selling its first major drug, Chirocaine, an anaesthetic used in surgical epidurals.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
0Comments